You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics Inc XNAS: VRDN

Viridian Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

13.76 0.63 (4.80%)

49.41% Fall from 52W High

984.1K XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Viridian Therapeutics Inc Key Metrics

Select

Market Capitalization

Below industry Median
1,121.2

PE TTM

Negative PE TTM
-4.2

PEG TTM

High in industry
0.3

Price to Book

Below industry Median
2.3

Institutional holding current Qtr %

High in industry
110.6

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-3.8

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-19.2

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-13.6

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-121,488.9

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-99,018.5

Piotroski Score

Low in industry
1

Rel Perf vs Sector quarter%

-24.7

ROE Annual %

Negative ROE Annual %
-75.2

RoA Annual %

Negative RoA Annual %
-43.8
All financials are in USD Million and price data in USD
VIEW MORE

9

S

9

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Viridian Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260100200Actual RevenueAvg. Estimate
Miss

Viridian Therapeutics Inc's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

Current EPS
-3.1
Avg. Estimate
-4.1
Low Estimate
-5.4
High Estimate
-3.3
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 34.2% in FY25

Consensus Recommendation

17 ANALYST Recommendations
BUY

Created with Highcharts 7.2.22Hold5Buy10Strong Buy

The consensus recommendation from 17 analysts for Viridian Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Viridian Therapeutics Inc Stock Analysis

Viridian Therapeutics Inc stock analysis with key metrics, changes, and trends.

Viridian Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$0.3 M3.82%negative

Annual Revenue fell 3.82%, in the last year to $0.3 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit$269.95 M13.55%negative

Annual Net Profit fell 13.55% in the last year to $269.95 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-4.15-negative

Price to Earning Ratio is -4.15, which is negative.

Stock Price$13.76-5.75%negative

Stock Price fell 5.75% and underperformed its sector by 14.9% in the past year.

Quarterly Net profit$79.72 M19.24%negative

Quarterly Net profit fell 19.24% YoY to $79.72 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio0.04-positive

Debt to Equity Ratio of 0.04 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-75.17 %-75.17%negative

Return on Equity(ROE) for the last financial year was -75.17%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding54.35 %-1.08%negative

Mutual Fund Holding decreased by 1.08% in the last quarter to 54.35.

Promoter Share Holding0.08 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 0.08%.

Interest Coverage Ratio-87.62-negative

Interest Coverage Ratio is -87.62, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

VIEW LESS


Loading data..

Viridian Therapeutics Inc - Company Profile

What does Viridian Therapeutics Inc do?

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Inc Management structure

All Gross Remunerations are in USD
Mr. Seth Harmon
Chief Financial Officer and Principal Accounting Officer
-
2025
Gross Remuneration
Year

Viridian Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Peter Harwin
Independent Director
-
2025
Gross Remuneration
Year
Dr. Christopher Cain, PhD
Director
-
2025
Gross Remuneration
Year
Mr. Jeffrey R. Ajer
Director
-
2025
Gross Remuneration
Year

Viridian Therapeutics Inc FAQ

How is Viridian Therapeutics Inc today?
Viridian Therapeutics Inc today is trading in the green, and is up by 4.80% at 13.76.
Viridian Therapeutics Inc is currently trading up 4.80% on an intraday basis. In the past week the stock rose 3.46%. stock has been down -25.26% in the past quarter and fell -5.75% in the past year. You can view this in the overview section.